OppenheimerFunds’s Kyntra Bio KYNB Stock Holding History

OppenheimerFunds’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$14.7M	Sell	10,809 -7	-0.1%	-$9.49K	0.02%	610
2018 Q4	$12.5M	Sell	10,816 -58	-0.5%	-$65.2K	0.02%	623
2018 Q3	$16.5M	Sell	10,874 -3,350	-24%	-$5.16M	0.02%	634
2018 Q2	$22.3M	Buy	14,224 +13	+0.1%	+$16.9K	0.03%	555
2018 Q1	$16.4M	Sell	14,211 -60	-0.4%	-$79K	0.02%	610
2017 Q4	$16.9M	Buy	14,271 +23	+0.2%	+$28.8K	0.02%	635
2017 Q3	$19.2M	Sell	14,248 -8	-0.1%	-$8.43K	0.02%	577
2017 Q2	$11.5M	Buy	14,256 +7	+0%	+$4.88K	0.01%	712
2017 Q1	$8.78M	Buy	14,249 +42	+0.3%	+$25.6K	0.01%	782
2016 Q4	$7.6M	Hold	14,207	–	–	0.01%	792
2016 Q3	$7.35M	Buy	14,207 +79	+0.6%	+$37.2K	0.01%	783
2016 Q2	$5.8M	Hold	14,128	–	–	0.01%	792
2016 Q1	$7.52M	Buy	+14,128	New	+$7.04M	0.01%	761

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OppenheimerFunds's KYNB Position: Q1 2019 in Review

OppenheimerFunds reduced its Kyntra Bio (KYNB) stake by 0.06% in Q1 2019, selling an estimated $9.49K and leaving 10,809 shares worth $14.7M. The position accounts for 0.02% of the portfolio, ranked #610.

OppenheimerFunds first reported a position in KYNB in Q1 2016 and has held it in 13 quarters since. The position peaked at $22.3M in Q2 2018. 225 funds tracked by Wall St. Rank hold KYNB as of Q1 2019.

OppenheimerFunds held 10,809 shares of Kyntra Bio worth $14.7M as of Q1 2019.
OppenheimerFunds sold 7 Kyntra Bio shares in Q1 2019, an estimated $9.49K.
Kyntra Bio made up 0.02% of OppenheimerFunds's portfolio in Q1 2019, its #610 holding.
OppenheimerFunds first reported a position in Kyntra Bio in Q1 2016 and has held it in 13 quarters since.
OppenheimerFunds's Kyntra Bio position peaked at $22.3M in Q2 2018.
225 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.